A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

NCT00000866 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MN rgp120/HIV-1
BIOLOGICAL: TBC-3B Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)